However, over the last years, tumor resistance mechanisms towards PARP inhibitor treatment were reported, such as reversion mutations in BRCA1 and BRCA2, loss of BRCA1 promoter hypermethylation, or overexpression of RAD51 [11]. This evidence concerns the gene PARP1 and neoplasm.